NRx Logo
  • Our Company
  • Our Science
    • Therapeutic Areas
      • Corona Virus / COVID-19
      • Psychiatry
    • Compounds Under Investigation
      • NRX-100 / NRX-101
      • ZYESAMI® (aviptadil)
      • For Physicians – Right to Try
    • NRx Pipeline
  • Pipeline
  • News & Media
  • Resources & Patient Stories
  • Investor Relations
  • Presentation
  • Careers
  • Contact Us
  • Search

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Sep 29, 2021 6:48am EDT

NRx Pharmaceuticals Announces Second Favorable Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19

Sep 27, 2021 7:04am EDT

NRx Pharmaceuticals Announces Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMI (aviptadil)

Sep 08, 2021 7:48am EDT

NRx Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

Aug 30, 2021 8:06am EDT

NRx Pharmaceuticals Announces New Finding from ZYESAMI™ (aviptadil) Phase 2b/3 Clinical Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19

Aug 26, 2021 6:48am EDT

NRx Pharmaceuticals to Work with Cardinal Health to Ensure Efficient Distribution of Potential Therapies

Aug 24, 2021 6:48am EDT

NRx Pharmaceuticals Announces Closing of $30 Million Private Placement

Aug 23, 2021 9:33am EDT

Participants in High Dose BriLife™ Investigational Vaccine Trial for COVID-19 Advised Booster Not Necessary

Aug 19, 2021 9:18am EDT

NRx Pharmaceuticals Announces $30 Million Private Placement

Aug 18, 2021 11:53am EDT

NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19

Aug 16, 2021 9:32pm EDT

NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 13
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
NRx
  • Home
  • Our Company
  • Our Science
  • Pipeline
  • News & Media
  • Resources & Patient Stories
  • Investor Relations
  • Careers
  • Contact Us
  • NRx on Facebook
  • NRx on Twitter
  • NRx on Linkedin
  • Forward Looking Statement
  • Privacy Policy
  • Terms of Use
  • © 2022 NRx Pharmaceuticals, Inc.

  • NRx on Facebook
  • NRx on Twitter
  • NRx on Linkedin